BBOT Drug Achieves First Monotherapy PanKRAS Response in Pancreatic Cancer; Positive Clinical Data & 2028 Cash Runway
BBOT sits 16% above its 52-week low of $8.5.
Summary
BridgeBio Oncology Therapeutics (BBOT) reported its fourth quarter and full-year 2025 financial results, accompanied by significant positive updates on its clinical pipeline. The company announced that its BBO-11818 panKRAS inhibitor achieved the first clinically confirmed monotherapy partial response in a patient with pancreatic ductal adenocarcinoma. Additionally, the BBO-8520 program, targeting KRAS G12C NSCLC, demonstrated a 65% objective response rate and a 68% 6-month progression-free survival, with a potentially differentiated safety profile. These strong clinical data points, combined with a cash runway extending into 2028, provide a positive outlook for the clinical-stage biopharmaceutical company, a subsidiary of BridgeBio Pharma (BBIO). Traders will be closely watching for multiple data readouts expected in the second half of 2026.
At the time of this announcement, BBOT was trading at $9.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $791.1M. The 52-week trading range was $8.50 to $14.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.